NF106: A neurofibromatosis clinical trials consortium phase II trial of the MEK inhibitor mirdametinib (PD-0325901) in adolescents and adults with NF1-related plexiform neurofibromas
Brian D. Weiss, Pamela L. Wolters, Scott R. Plotkin, Brigitte C. Widemann, James H. Tonsgard, Jaishri Blakeley, Jeffrey C. Allen, Elizabeth Schorry, Bruce Korf, Nathan J. Robison, Stewart Goldman, Alexander A. Vinks, Chie Emoto, Tsuyoshi Fukuda, Coretta T. Robinson, Gary Cutter, Lloyd Edwards, Eva Dombi, Nancy Ratner, Roger PackerJ. Fisher
Research output: Contribution to journal › Article › peer-review
Fingerprint
Dive into the research topics of 'NF106: A neurofibromatosis clinical trials consortium phase II trial of the MEK inhibitor mirdametinib (PD-0325901) in adolescents and adults with NF1-related plexiform neurofibromas'. Together they form a unique fingerprint.